VolitionRX Limited

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to Village and Rx Limited's fourth quarter and full year 2020 earnings conference call. During today's presentation, all parties will be in listen-only mode. Following the presentation, the conference call will be open for questions. If you have a question, please press the star key followed by the number 1 on your touch-tone telephone. If you'd like to withdraw your question, please press the star key followed by the number 2. If you're using speaker equipment, please lift the handset before making your selections. This conference is being recorded today, March 23, 2021. I'd now like to turn the conference call over to Mr. Scott Powell.

Please go ahead, Scott. Thank you, and welcome, everyone, to today's earnings conference call for VolitionRx Limited. This call will cover Volition's financial and operating results for the fourth quarter and full year of 2020. along with a discussion of our recent activities and key upcoming milestones. Following our prepared remarks, we will open the conference call to a question and answer session. Also on our call today are Mr. Cameron Reynolds, President and Chief Executive Officer, Mr. Terry Cuse, our recently appointed Chief Financial Officer, and Dr. Jake McAuliffe, our Chief Scientific Officer. Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, These statements involve risks, uncertainties, and assumptions. Actual future results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results, performance, or achievements expressed or implied by these statements. We have identified various risk factors associated with our operations in our most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the Securities and Exchange Commission. We do not undertake any obligation to update any forward-looking statements made during the course of this call. I'd now like to turn the call over to our President and Chief Executive Officer, Mr. Cameron Reynolds. Cameron?

Thank you everyone for joining Volition's conference call today. I especially appreciate it given the busy earnings call season. I'd like to start yet again by recognizing the amazing commitment and hard work shown by all of our team over the past year during these difficult times. I could not be prouder of their efforts. Despite the lockdown, we have managed to keep our main lab in Namur operational, and opened the new SilverOne production facility and indeed have made such varied and significant progress in so many areas of the business throughout 2020 and into the first quarter of 2021. Now that we have such a stable, reliable, reproducible platform technology that we think can and will be highly disruptive and influential worldwide in a wide range of areas. Before passing over to Tarek who will cover the financials and then moving on to our product launches, this being our annual call, I will start today by briefly discussing our 2020 highlights as a reminder of all the progress we have made in the last year. We bookended this year strongly, firstly by closing our acquisition of Optima in January, and then by launching our first product, the NUQ Vet Cancer Screening Test in December, and achieved lots of exciting milestones in between. As a reminder, the strategic acquisition of Optima helped secure the supply of one of the key components of our NUQ test, the recumbent nucleosomes, which we use as the calibrant. The transfer of know-how is now complete, and we now have the capability to manufacture a wide range of these key components in-house. 2020 was a pivotal year for NUQVet. It is truly remarkable to reflect that we only reported the proof of concept data in April of last year, and yet by the Veterinary Cancer Society Conference in October of 2020, we published all study results hosted a key opinion leader roundtable event, and by year end, launched a new QVET cancer screening test with Texas A&M. This is all a truly fantastic team effort, and refocusing on near-term product launch opportunities during the pandemic showed the amazing flexibility of our platform and team. This flexibility is a key aspect of our success. Throughout the year, we, as always, continue to strengthen our large intellectual property portfolio with additional patents being granted and new patent applications submitted, including in relation to the use of NUQ technology in mitosis, COVID-19, and other diseases. And we now hold 64 patents worldwide, with a further 90 patent pending. We also published and or presented at a number of conferences, most notably at ASCO 2020, with varied abstracts featuring performance data on our NUQ technology with respect to lung cancer and blood cancer, as well as performance data on NUQ capture. At our virtual market day in October, we announced our commitment to two blood cancer studies, both to be conducted in the US. The first of these studies is a large-scale, up to 1,500 subjects, regulatory study into the five most common types of non-Hodgkin's lymphoma. And the second is a proof-of-concept study for the monitoring of treatment response for the most aggressive NHL cancer, Both studies are now underway, with results from the treatment response study expected later in the first half of this year, and likely the first readout from the NHL Regulatory 4510 case study within the next year. So we have had an action-packed 2020 and have a lot to review from the start of 2021. But before I go into more details, please allow me to introduce our new Chief Financial Officer, Terry Cuse. that will take you through the key financial results for 2020 and provide an update on the recent financing transactions that have significantly strengthened our cash position. Tarek, great to have you on board. Over to you.